c-Met and RON expression levels in endometrial adenocarcinoma tissue and their relationship with prognosis

Objective: To investigate the potential relevance of c-Met and RON gene expression in patients with adenocarcinoma of the endometrium and analyze the relationships among the c-Met and RON expression, clinicopathological characteristics, and patient survival. Materials and Methods: The study included 60 cases diagnosed with endometrial adenocarcinoma with more than five-years follow-up. Total RNA from formalin-fixed paraffin-embedded tissues of 60 adenocarcinomas of the endometrium and normal endometrium tissues were isolated for c-Met and RON quantitative analysis by real-time real-time polymerase chain reaction (RT-PCR). Results: The c-Met and RON expression in endometrial adenocarcinoma was significantly higher than that in normal endometrial tissues (p < 0.01), with average up-regulated levels of 3.94 ± 1.88 and 2.74 ± 0.88, respectively. Moreover, high c-Met expression was significantly correlated with the histological stage (p = 0.017), and high RON expression was related to histological stage (p = 0.035), muscle invasion (p = 0.006), and lymph node metastasis (p = 0.018). Multivariate Cox regression analysis revealed that the co-expression of c-Met and RON was an independent prognostic factor for adenocarcinoma of the endometrium and was significantly associated with decreased overall survival (HR = 3.571, p = 0.014). Conclusion: The co-expression of c-Met and RON is associated with a poor prognosis in endometrial adenocarcinoma and is an independent prognostic marker for endometrioid adenocarcinoma.

c-Met; RON; Endometrioid adenocarcinoma; Prognosis.

[1] Edakuni G., Sasatomi E., Satoh T., Tokunaga O., Miyazaki K.: “Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma”. Pathol. Int., 2001, 51, 172.

[2] Chen Y.Q., Zhou Y.Q., Fisher J.H., Wang M.H.: “Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo”. Oncogene, 2002, 21, 6382.

[3] Peace B.E., Hughes M.J., Degen S.J., Waltz S.E.: “Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis”. Oncogene, 2001, 20, 6142.

[4] Maggiora P., Lorenzato A., Fracchioli S., Costa B., Castagnaro M., Arisio R.: “The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness”. Exp. Cell Res., 2003, 288, 382.

[5] Cheng H.L., Liu H.S., Lin Y.J., Chen H.H., Hsu P.Y., Chang T.Y., et al.: “Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder”. Br. J. Cancer, 2005, 92, 1906.

[6] Livak K.J., Schmittgen T.D.: “Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method”. Methods, 2001, 25, 402.

[7] Rupp G.M., Locker J.: “Purification and analysis of RNA from paraffin- embedded tissues”. Biotechniques, 1988, 6, 56.

[8] Li J., Smyth P., Flavin R., Cahill S., Denning K., Aherne S., et al.: “Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells”. BMC Biotechnol., 2007, 7, 36.

[9] Follenzi A., Bakovic S., Gual P., Stella M.C., Longati P., Comoglio P.M.: “Cross-talk between the proto-oncogenes Met and Ron”. Oncogene, 2000, 19, 3041.